Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KRMD 
Repro Med Systems Inc (KRMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: KRMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 4 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 11.36% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 172.11M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 5 | Beta 0.43 | 52 Weeks Range 1.86 - 5.05 | Updated Date 07/11/2025 |
52 Weeks Range 1.86 - 5.05 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.1% | Operating Margin (TTM) -12.92% |
Management Effectiveness
Return on Assets (TTM) -13.09% | Return on Equity (TTM) -29.87% |
Valuation
Trailing PE - | Forward PE 188.68 | Enterprise Value 168023658 | Price to Sales(TTM) 4.91 |
Enterprise Value 168023658 | Price to Sales(TTM) 4.91 | ||
Enterprise Value to Revenue 4.79 | Enterprise Value to EBITDA -17.15 | Shares Outstanding 46141000 | Shares Floating 33853187 |
Shares Outstanding 46141000 | Shares Floating 33853187 | ||
Percent Insiders 7.6 | Percent Institutions 51.82 |
Upturn AI SWOT
Repro Med Systems Inc
Company Overview
History and Background
Repro Med Systems, Inc., doing business as KORU Medical Systems, was founded to develop, manufacture, and market medical devices for various therapies. It has evolved to focus on home infusion solutions.
Core Business Areas
- Infusion Therapy: KORU Medical Systems focuses on infusion therapy, particularly subcutaneous infusion. This includes devices and consumables used for delivering medications and fluids directly under the skin.
Leadership and Structure
KORU Medical Systems has a leadership team comprising executives with experience in medical devices and finance. The organizational structure involves departments for R&D, manufacturing, sales, marketing, and administration.
Top Products and Market Share
Key Offerings
- Freedom System: The Freedom System, including the Freedom60 and FreedomEdge Syringe Infusion Drivers and related consumables (HIgH-Flo Subcutaneous Safety Needle Sets and tubing), provides ambulatory infusion for patients. Market share data is not publicly available, but its competitors include Smiths Medical and Baxter International. High-Flo needles aim to maximize flow rates of infusates. Revenue is mainly related to the sale of the Freedom System.
Market Dynamics
Industry Overview
The infusion therapy market is driven by the increasing prevalence of chronic diseases and the growing demand for home healthcare. Advancements in infusion technology and the development of biocompatible materials also contribute to market growth.
Positioning
KORU Medical Systems is positioned in the ambulatory infusion segment, focusing on subcutaneous delivery. Its competitive advantage lies in its user-friendly devices and specialized needle sets. It competes with larger players in the infusion pump market.
Total Addressable Market (TAM)
The TAM for infusion therapy is estimated to be multi-billion dollars globally. KORU Medical Systems targets a niche within this market, focusing on specific infusion needs and patient populations. Actual numbers vary across industries and depend on the study. Positioned to grow within its focused market by increasing adoption within the subcutaneous market.
Upturn SWOT Analysis
Strengths
- Specialized focus on subcutaneous infusion
- User-friendly device design
- Proprietary needle technology
- Strong brand recognition within its niche
Weaknesses
- Limited product portfolio
- Dependence on a single core technology
- Small market capitalization relative to competitors
- Reliance on third-party manufacturers
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships with pharmaceutical companies
- Geographic expansion into international markets
- Development of next-generation infusion devices
Threats
- Competition from larger medical device companies
- Technological advancements by competitors
- Changes in healthcare regulations and reimbursement policies
- Product recalls or safety concerns
Competitors and Market Share
Key Competitors
- BDX
- BAX
- ITCI
Competitive Landscape
KORU Medical Systems faces competition from larger medical device companies with broader product portfolios and greater resources. Its competitive advantage lies in its focus on subcutaneous infusion and user-friendly devices.
Growth Trajectory and Initiatives
Historical Growth: Discuss KORU Medical Systems' growth trends over the past years, focusing on sales of its Freedom system and any new market penetration.
Future Projections: Provide projections for KORU Medical Systems' future growth based on analyst estimates and the company's strategic initiatives.
Recent Initiatives: Highlight recent strategic initiatives undertaken by KORU Medical Systems, such as new product launches, partnerships, or acquisitions.
Summary
KORU Medical Systems specializes in subcutaneous infusion therapy with its Freedom System. It is a smaller player facing stiff competition from larger medical device companies. Its strengths include a specialized focus and user-friendly design. Growth opportunities lie in expanding into new markets and therapeutic areas, while it needs to watch out for competitive advancements and healthcare regulations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repro Med Systems Inc
Exchange NASDAQ | Headquaters Mahwah, NJ, United States | ||
IPO Launch date 1996-03-20 | President, CEO & Director Ms. Linda M. Tharby | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 80 | Website https://www.korumedical.com |
Full time employees 80 | Website https://www.korumedical.com | ||
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.